Early Salvage Therapy for Patients With Advanced Features for Biochemical Relapse After Radical Prostatectomy for Localized Prostate Carcinoma In Correlation With Supposed Molecular-genetic Parameters of Higher Aggressiveness
Pathologically confirmed invasive prostate carcinoma with minimal 1 risk factor (RF) after radical prostatectomy (RP)
Patient refuses the adjuvant therapy after normalization of urinary function within 6 month after RP
Signed informed consent to participate in the study and (where necessary) consent to participate in the translational part of the research (not a requirement)
ECOG 0 - 1
pT2 and minimal 1 risk factor (RF):
* R1 (PSM), and/or
* Gleason score (4+3=7) 8-10 and/or ISUP grade group 3-5
pT3a /pT3b with or without one RF
No evidence of suspicious pelvic lymph nodes by initial diagnostic: cN0 and/or pN0
No evidence of suspicious distant metastases by initial diagnostic: M0
Patient with decline of PSA level to undetectable PSA levels (\< 0,1 ng/ml) or around 0,2ng/ml and with another decreasing trends so that the PSA level decline within 12-24 weeks after RP to undetectable levels (\< 0,1 ng/ml) and with renewed increase of PSA \>0,2 ng/ml (BCR= biochemical relapse) without any clinical relapse on PSMA PET/CT
No hormonal therapy prior and /or after the radical prostatectomy
Patient suitable and fit for subsequent radiotherapy with high likelihood of good compliance to the follow-up
You may not be if
Life expectancy (based on Charlson comorbidity index) \< 10 years
Patient not fit for the therapy
History of other cancer (other than a radically removed non-melanoma skin carcinoma)
Previous pelvic irradiation
Active immunosuppressive medication
History of hormone therapy prior to randomization
cN1 and/or pN1 and M1
Clareo Health | Early Salvage Therapy for Patients With Advanced Features for Biochemical Relapse After Radical Prostatectomy for Localized Prostate Carcinoma In Correlation With Supposed Molecular-genetic Parameters of Higher Aggressiveness
